00656.HK --


More News

  • Fosun Showcases LANVIN, Oriental Haute Couture and Yuyuan Original at WDCC 2023


    On September 26, the 2023 World Design Cities Conference (WDCC) opened at the Huangpu Riverside with the theme of "Design Beyond Creativity". The event was organized by the Shanghai Municipal People's Government. As a supporting partner, Fosun, which has been rooted in Shanghai for more than 30 years, and its subsidiaries, Yuyuan and Lanvin Gro

  • Fosun International’s FTSE Russell ESG Rating Upgraded to 3.8, Maintains Inclusion in FTSE4Good Index Series


    The world’s leading index company, FTSE Russell, recently announced the latest ESG (Environmental, Social and Governance) rating results of Fosun International Limited (HKEX stock code: 00656, “Fosun International”).Fosun International’s FTSE Russell ESG rating consistently outperforms the global industry average and the country averageIn 2023, Fosun I

  • STORE OF THE DAY AUTUMN 2023: Tom Tailor Launches New Store Design in Vienna


    "TextilWirtschaft" is a leading German languagemagazine in the fashion and textile industry. It covers various aspects of the fashion business, including trends, market analysis, retail strategies, and industry news. "TextilWirtschaft" provides valuable insights and information for professionals in the textile and fashion sectors

  • Fosun International has been awarded the “ESG Benchmark Awards”


    (26 September 2023,Hong Kong)The ESG Achievement Awards 2022/2023 (the “Awards”) Ceremony was held inHong Kong on 22 September. Fosun International was awarded the “ESG Benchmark Awards” Silver Award in recognition of its efforts and outstanding performances in the environmental protection, social responsibility, and corporate governance aspects.With strong supp

  • Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC


    Shanghai, China, 22 September 2023 – Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the first-line treatment of pa